On behalf of Massimo Colombo, MD, meeting chairman, we are pleased to invite you to the Enhancing Clinical Outcomes in Hepatocellular Carcinoma: A Multidisciplinary Expert Practice^SM Meeting in Berlin, Germany, on 3 December 2011.

During this meeting, leaders in the field will discuss, in an interactive format, clinical issues encountered daily by practicing physicians.

For available travel grants, please contact travelgrants@prIMEoncology.org.

Hotel Berlin
Luetzowplatz 17 
10785 Berlin, Germany

This educational activity is designed for pan-European medical oncologists, hepatologists, surgical oncologists, radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with hepatocellular carcinoma. This meeting is restricted to healthcare professionals based outside of the United States.

Upon completion of this educational activity, participants should be able to:

• Discuss the epidemiology and risk factors for hepatocellular carcinoma (HCC), and discuss strategies for screening and surveillance
  
  
• Examine the current understanding of HCC tumor biology with regard to gene profiling, molecular targets, biomarkers, and risk-assessment strategies
  
  
• Evaluate the latest treatment approaches for early-stage and intermediate-stage HCC, including diagnostic procedures, radiation and embolization techniques, and surgical strategies
  
  
• Describe current standards of care and recent advances in the treatment of advanced unresectable HCC, including the role of targeted therapies, patient selection, and appropriate response-monitoring strategies
  
  
• Discuss the efficacy and safety of treatment options for patients with metastatic HCC beyond first-line therapy, including chemotherapy and novel targeted agents
  
  
• Identify the importance of a multidisciplinary approach in the treatment of patients with HCC

Chair Massimo Colombo, MD University of Milan Milan, Italy

Faculty Ghassan Abou-Alfa, MD Memorial Sloan-Kettering Cancer Center New York, New York, United States

René Adam, MD, PhD Paul Brousse Hospital Villejuif, France

Laura Crocetti, MD, PhD University of Pisa Pisa, Italy

Philip Johnson, MD, FRCP University of Birmingham Birmingham, United Kingdom

Hans Christian Spangenberg, MD University of Freiburg Freiburg, Germany

Jessica Zucman-Rossi, MD, PhD University Paris Descartes Paris, France

prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.